Cargando…
Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favora...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090332/ https://www.ncbi.nlm.nih.gov/pubmed/25025013 http://dx.doi.org/10.5045/br.2014.49.2.115 |
_version_ | 1782480613352144896 |
---|---|
author | Jo, Jungmin Yoon, Dok Hyun Lee, Sang Wook Park, Chan-Sik Huh, Jooryung Lee, Kyoungmin Kang, Eun Hee Kim, Shin Suh, Cheolwon |
author_facet | Jo, Jungmin Yoon, Dok Hyun Lee, Sang Wook Park, Chan-Sik Huh, Jooryung Lee, Kyoungmin Kang, Eun Hee Kim, Shin Suh, Cheolwon |
author_sort | Jo, Jungmin |
collection | PubMed |
description | BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection. METHODS: We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010. RESULTS: With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively. CONCLUSION: These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL. |
format | Online Article Text |
id | pubmed-4090332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-40903322014-07-14 Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection Jo, Jungmin Yoon, Dok Hyun Lee, Sang Wook Park, Chan-Sik Huh, Jooryung Lee, Kyoungmin Kang, Eun Hee Kim, Shin Suh, Cheolwon Blood Res Original Article BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection. METHODS: We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010. RESULTS: With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively. CONCLUSION: These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014-06 2014-06-25 /pmc/articles/PMC4090332/ /pubmed/25025013 http://dx.doi.org/10.5045/br.2014.49.2.115 Text en © 2014 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jo, Jungmin Yoon, Dok Hyun Lee, Sang Wook Park, Chan-Sik Huh, Jooryung Lee, Kyoungmin Kang, Eun Hee Kim, Shin Suh, Cheolwon Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title_full | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title_fullStr | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title_full_unstemmed | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title_short | Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection |
title_sort | abbreviated chemotherapy for limited-stage diffuse large b-cell lymphoma after complete resection |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090332/ https://www.ncbi.nlm.nih.gov/pubmed/25025013 http://dx.doi.org/10.5045/br.2014.49.2.115 |
work_keys_str_mv | AT jojungmin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT yoondokhyun abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT leesangwook abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT parkchansik abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT huhjooryung abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT leekyoungmin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT kangeunhee abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT kimshin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection AT suhcheolwon abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection |